Helixgate https://validator.w3.org/feed/docs/rss2.html STAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and more Home Epic’s alleged anticompetitive practices under scrutiny from federal, state investigators Luigi Mangione pleads guilty to federal stalking charges in the killing of UnitedHealthcare CEO Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene BMS’s New Facility, Recursion–Genentech Partnership, Long-COVID and Persistent C. auris Capricor soars on potential FDA review extension, filing amendments SFA Spectroscopy Chases Away Cloudy Samples STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more STAT+: Drug-testing lab that has sparked controversy sues group that develops drug standards over criticism This week in Drug Discovery (10-14 August 2026)  Skye and Redx form new entity with $125M to advance fibrosis assets STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class BMS welcomes new multiple myeloma drug as generics batter current portfolio Pressure piles on Amgen after EU pulls Tavneos, flags ‘serious breaches’ in pivotal study STAT+: Commure terminates payments under its customer referral programs tied to AI products Advancing Microbial-Derived Biologics from Scale-Up to Commercial Production New Taiho, Cullian data heats up lung cancer drug battle Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition CN Bio awarded Innovate UK grant to reduce animal testing Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale Biotech initiatives pick up as more regions race to become hubs Two years after rules overhaul, have methadone clinics really changed? Nascent US psychedelic therapy opportunity attracts overseas manufacturers Thermo and Michael J. Fox Foundation Collaborate to Advance Proteomics-Enabled Parkinson’s Therapy Dynamism and evolvability in nucleic acid enzymes The Italian inflection point: Clinical strength, culture and capital A 236-million-year-old fossil could rewrite the story of mammalian birth Talks on launch of clinical trial of Ebola vaccine in DRC advance, WHO says  Opinion: How to disrupt the health misinformation business model STAT+: As young people increasingly get cancer, new fertility options are changing their futures Behind the bell: gearing up to go public July’s biopharma layoffs affect 466 employees, a 94% year-over-year drop Proteome-wide identification of the druggable CRBN interactome In Vivo Protein Generation Using Nanoparticle Delivery: Emerging Platforms and CMC Strategies Cancer-Fighting Abilities of NK Immune Cells May Be Disrupted by Some Omega Fatty Acids Trump administration’s new ‘treatment-first’ addiction toolkit emphasizes faith, abstinence  Biopharma’s Drawdown Is a Chance to Build Biotech Back Better WHO says Trump’s latest vaccine policy order is misguided Software Can Solve CGT’s Sectors Traceability Challenges Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug Next 10 U.S. Biopharma Clusters 2026 IPO stock tracker: How newly public biotechs are performing Definium’s LSD asset beats analyst expectations in Phase 3 anxiety readout AI clinical monitoring agent can deliver up to 82 times the ROI in oncology: report PDS halts work on phase 3 cancer therapy to focus on colorectal contender Lilly cracks down on black market for obesity asset retatrutide with six lawsuits Opinion: AAP president: How pediatricians are navigating federal leaders’ fear-mongering on vaccines STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk